Beijing SL Pharmaceutical Co., Ltd.

Sümbol: 002038.SZ

SHZ

8.62

CNY

Turuhind täna

31.0841
P/E suhe
2.4867
PEG suhe
8.86B
MRK Cap
0.01%
DIV tootlus

Beijing SL Pharmaceutical Co., Ltd. (002038-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 781.662 M, mis on 0.214 % gowth. Kogu perioodi keskmine brutokasum on 586.377 M, mis on 0.211 %. Keskmine brutokasumi suhtarv on 0.739 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.778 %, mis on võrdne 0.144 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Beijing SL Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.068. Käibevara valdkonnas on 002038.SZ aruandlusvaluutas 2639.981. Märkimisväärne osa neist varadest, täpsemalt 2133.016, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 1.883%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 1587.258, kui neid on, aruandlusvaluutas. See näitab erinevust 22.554% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 0 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.000%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 5800.616 aruandlusvaluutas. Selle aspekti aastane muutus on 0.061%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 236.214, varude hind on 144.46 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 1143.67.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002
balance-sheet.row.cash-and-short-term-investments	5056.78	2133	739.9	990.2	837.3	1401.3	1195.9	1509.1	1208.2	1508.3	866.3	769.3	669.8	581.6	457.5	440	433	292.9	205.7	195.4	237.8	45.9	11.7	3.7
balance-sheet.row.short-term-investments	2289.51	1449.2	144.9	162.4	173.8	140.5	29.7	70.3	36.5	38.7	9.5	6.4	8.9	8.8	11.6	21.9	12.2	31	0	0	0	14	0	0
balance-sheet.row.net-receivables	1134.59	236.2	406.4	534	649.9	841.2	847.5	812.2	795	795.3	892.7	637.6	587.9	383.1	202.8	241.6	179.1	147.1	133.6	75.3	37.7	31.4	29.6	34.7
balance-sheet.row.inventory	625.05	144.5	136.8	124.8	112	108.3	251.3	275.7	198.2	129.7	112.2	110.9	57	64.6	29.5	24.4	8.6	6.1	7.5	8.2	7.7	9.2	3.9	1.1
balance-sheet.row.other-current-assets	2585.99	126.3	714.5	648.7	608.1	514.4	508.5	456	536.2	150.9	411.8	208.1	181.1	160	75.5	53	15.8	-0.1	0	14.8	0	0	-0.1	-0.1
balance-sheet.row.total-current-assets	9402.41	2640	1997.7	2297.7	2207.3	2865.3	2803.2	3053	2737.7	2584.2	2283	1725.9	1495.8	1189.2	765.3	758.9	636.5	446.1	346.8	293.6	283.2	86.5	45.2	39.3
balance-sheet.row.property-plant-equipment-net	2044.8	538.4	527.3	604	589.2	588	559.3	556.3	481.1	459.8	414.1	359.3	331.9	197.9	182.2	101.8	103.3	110.5	99.2	94.1	73.2	46.8	46.2	27.8
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	4425.3	1143.7	978.5	872.8	713.7	641.2	708.8	363.2	259.2	218.7	198.4	184.5	107.9	78.8	67.8	53.5	30	22.1	15.6	18.2	18.9	18.6	11.5	10.1
balance-sheet.row.goodwill-and-intangible-assets	4425.3	1143.7	978.5	872.8	713.7	641.2	708.8	363.2	259.2	218.7	198.4	184.5	107.9	78.8	67.8	53.5	30	22.1	15.6	18.2	18.9	18.6	11.5	10.1
balance-sheet.row.long-term-investments	5601.25	1587.3	1295.1	1241.3	1077.7	447.9	490.4	138.8	255.8	218.8	216	329	247.4	211.6	215	50.4	4.9	-24.1	0	0	0	0	0	0
balance-sheet.row.tax-assets	77.69	0	39.5	27.7	25.4	22.6	14.4	23.8	18	14.3	10.5	6.9	7.3	10.3	3.7	3.9	1.6	1.1	1	0	0	0	0	0
balance-sheet.row.other-non-current-assets	3192.71	368.4	1037.7	717	781.6	659.9	412.2	449.9	329.5	265.9	196.9	106.5	26.3	48.4	14.5	51.3	12.2	31	-1	0	14.4	0	0	0
balance-sheet.row.total-non-current-assets	15341.75	3637.8	3878.2	3462.7	3187.5	2359.6	2185.1	1532	1343.6	1177.5	1036	986.2	720.9	547	483.3	260.9	152	140.6	114.8	112.3	106.6	65.4	57.7	37.8
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	24744.16	6277.8	5875.8	5760.5	5394.8	5225	4988.3	4585.1	4081.3	3761.6	3319.1	2712.1	2216.7	1736.1	1248.6	1019.8	788.5	586.6	461.6	405.9	389.8	151.8	102.8	77.1
balance-sheet.row.account-payables	778.6	213.2	176.2	191.4	179.9	178.5	264.9	111.5	30.9	39.8	42.7	36.5	27.1	9.6	8.1	11.8	11.6	14.6	14.4	8.4	19.3	4.4	5.1	0.2
balance-sheet.row.short-term-debt	46.32	37.6	-27.9	0.2	5.5	3.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	19.2	0	1.5
balance-sheet.row.tax-payables	11.48	0	9	16.3	13.7	25.8	51	65.1	46.8	44.2	50.7	46.2	41.7	21.9	20.8	13.5	5.8	5.2	4.1	1.7	-0.9	-1.2	1.5	0.6
balance-sheet.row.long-term-debt-total	0	0	0	2.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Deferred Revenue Non Current	185.63	47	51.4	56.2	61	65.3	29.2	33.1	33.5	33.2	17.5	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	223.42	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	379.81	107.3	112.7	1.6	1.5	14.2	175.6	138.2	82.8	71.2	73.1	67.1	65.2	35.6	29.2	20.4	14.3	17.6	11.6	8.9	3	1.7	6.5	0
balance-sheet.row.total-non-current-liabilities	362.01	47.4	107.8	109.3	95.1	71.1	29.2	36	37.5	37.4	22.2	19.6	12.9	5.3	0	4.5	0	2.5	9.4	6.1	6.1	4.4	5.6	3.6
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	0	0	0	2.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	1621.95	420.7	396.6	434.2	410.1	403.8	469.7	285.7	151.2	148.4	137.9	123.1	105.2	50.5	37.2	36.8	25.9	34.7	35.4	23.4	28.4	36.8	17.2	10.8
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	4109.4	1027.3	1027.3	1027.3	1027.3	1027.3	684.9	684.9	684.9	684.9	456.8	456.8	380.7	380.7	253	251.4	248.4	124.2	82.8	82.8	69	50	40	40
balance-sheet.row.retained-earnings	16182.54	4077.8	3763.8	3632.1	3308.9	3184.1	3272.9	3129.9	2787.7	2518.8	2364	1826.6	1478.8	1118.5	804	602.1	426	236.4	129.4	92.4	77.5	50.2	37.7	21.3
balance-sheet.row.accumulated-other-comprehensive-income-loss	2743.99	695.1	676.5	651.9	638.2	596.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	0.86	0.4	0.4	0.1	0.1	0.1	540.1	455.8	423.9	374.1	327.1	282.2	180.6	124.7	133.8	112	86	190.7	213.3	206.7	214.9	14.7	7.9	5
balance-sheet.row.total-stockholders-equity	23036.79	5800.6	5468.1	5311.5	4974.6	4808.2	4497.8	4270.6	3896.5	3577.8	3147.9	2565.7	2040.1	1624	1190.8	965.5	760.4	551.3	425.6	381.9	361.4	115	85.6	66.3
balance-sheet.row.total-liabilities-and-stockholders-equity	24744.16	6277.8	5875.8	5760.5	5394.8	5225	4988.3	4585.1	4081.3	3761.6	3319.1	2712.1	2216.7	1736.1	1248.6	1019.8	788.5	586.6	461.6	405.9	389.8	151.8	102.8	77.1
balance-sheet.row.minority-interest	38.37	9.4	11.2	14.7	10.1	13	20.7	28.8	33.6	35.4	33.2	23.3	71.4	61.6	20.6	17.5	2.2	0.7	0.6	0.6	0.1	0.1	0	0
balance-sheet.row.total-equity	23075.16	5810	5479.2	5326.2	4984.7	4821.2	4518.5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	24744.16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	7890.75	3036.4	1440.1	1403.6	1251.5	588.4	520	209.1	292.3	257.6	225.5	335.4	256.3	220.3	226.6	72.3	17.1	6.9	0	0	0	14	0	0
balance-sheet.row.total-debt	75.19	37.6	0	2.5	5.5	3.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	19.2	0	1.5
balance-sheet.row.net-debt	-2692.08	-646.2	-595	-825.4	-658	-1256.9	-1166.2	-1438.8	-1171.7	-1469.6	-856.8	-763	-660.9	-572.8	-445.9	-418.1	-420.8	-261.9	-205.7	-195.4	-236.8	-12.7	-11.7	-2.2

Rahavoogude aruanne

Beijing SL Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.216 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab -0.000 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 36.56 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -540403356.360. See on 1.732 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 113.88, -22.21, 0, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -102.73 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 0, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009	2007	2005	2003
cash-flows.row.net-income	284.9	228.3	421.3	361.5	479.5	563.4	528.8	447.4	577.2	701	572	480	524.4	276.4	243.7	218.4	134.8	50.3	33.8	32	31.2
cash-flows.row.depreciation-and-amortization	6.41	113.9	99.8	89.5	76.6	55.8	37.5	33.6	32.7	30.7	22.5	20.3	17.6	13.7	12.3	11.9	9.9	7.4	10	9.1	8
cash-flows.row.deferred-income-tax	0	-6.3	14.4	25.6	-7.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	0	6.3	-14.4	-25.6	7.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	15.41	113.7	129.1	197.9	141.7	-142	30.2	-57.2	-45.1	-226.2	-213.3	-75.3	-95.9	-35.6	-66.9	-48.8	-14.3	4	6	-10.1	-9.8
cash-flows.row.account-receivables	19.66	82.9	108.6	198.8	-9.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-4.25	0.6	-11.5	-3.7	142.9	24.4	-77.5	-68.5	-17.5	-1.3	-53.9	7.6	-35	-5.2	-15.6	-2.5	1.4	0.6	-0.5	1.5	-5.3
cash-flows.row.account-payables	0	36.6	17.5	-22.7	15.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	0	-6.3	14.4	25.6	-7.1	-166.4	107.7	11.3	-27.7	-224.9	-159.4	-82.9	-60.8	-30.4	-51.3	-46.3	-15.7	3.4	6.5	-11.6	-4.6
cash-flows.row.other-non-cash-items	269.47	-66.1	-185.6	-233.1	-31.9	7.9	-215.8	-26.9	-60	-40.6	-33.8	-26.4	-217.5	-16.4	-14.8	12.8	-42.1	-4.2	-2.4	0.3	1.2
cash-flows.row.net-cash-provided-by-operating-activities	481.62	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-213.1	-163.5	-236.9	-255.9	-272.8	-227.4	-229.6	-164.2	-129.7	-151	-109.5	-247.9	-73.1	-43	-30.5	-23.6	-26.6	-64.9	-81.2	-17.7	-16.4
cash-flows.row.acquisitions-net	0.01	-3.4	16.5	0	0	227.4	229.7	164.2	-6.8	151.3	0	0.4	0.3	0	0	23.6	27.5	64.9	81.2	0	0
cash-flows.row.purchases-of-investments	-582.01	-1247.4	-1061	-1517.2	-579.9	-987.6	-64.8	-485.4	-146.7	-210.9	-229.6	-752.1	-904.5	-142.7	-107.6	-16.8	-103.9	-196.1	-173	0	-14
cash-flows.row.sales-maturities-of-investments	487.59	896.1	1092.6	964.3	469.3	799.3	315.5	79	526.7	74.7	208.6	714.1	894.2	17	6.5	21.5	210.8	282.3	6.3	0	0
cash-flows.row.other-investing-activites	-71.42	-22.2	-9	-33.3	0.1	-227.4	-229.6	-164.2	0	-151	-19.6	37.1	0.6	4.3	-4.7	-23.6	-26.6	-64.9	-81.2	0	0
cash-flows.row.net-cash-used-for-investing-activites	-383.53	-540.4	-197.8	-842.1	-383.2	-415.7	21	-570.7	243.5	-287	-150.1	-248.4	-82.5	-164.4	-136.2	-18.9	81.1	21.2	-247.9	-17.8	-30.4
cash-flows.row.debt-repayment	0	0	-11	-5.6	-3.9	0	0	0	0	0	-0.3	-76.1	0	0	0	0	0	0	-1	-19.2	0
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	-102.7	-102.9	-205.8	-205.6	-342.4	-137	-137	-137	-91.4	-95.2	0	-63.2	-50.3	-49.7	-12.4	-13.2	-8.3	-13.8	-4.7	-0.2
cash-flows.row.other-financing-activites	0	0	10.6	4.5	10.5	0	2.3	12.8	14	-3.5	0.6	13.5	44	4.3	8.8	1	0	4.7	2.8	216.3	20.3
cash-flows.row.net-cash-used-provided-by-financing-activities	-110.25	-102.7	-103.3	-206.9	-199	-342.4	-134.7	-124.2	-123	-94.8	-94.9	-62.6	-19.2	-45.9	-40.9	-11.4	-13.2	-3.6	-12	192.4	20.1
cash-flows.row.effect-of-forex-changes-on-cash	0.03	0.1	0	0.1	0.2	0.3	0	0.1	-1.1	-0.9	-0.3	0.6	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	-153.55	-253.2	163.5	-633.1	83.9	-272.6	267.1	-297.8	624.4	82.2	102.1	88.1	126.9	27.8	-2.7	163.9	156.3	75.2	-212.4	205.9	20.2
cash-flows.row.cash-at-end-of-period	2465.46	527.2	780.4	617	1250.1	1166.2	1438.8	1171.7	1469.6	845.2	763	660.9	572.8	445.9	418.1	420.8	256.9	100.6	25.4	237.8	31.9
cash-flows.row.cash-at-beginning-of-period	2619.01	780.4	617	1250.1	1166.2	1438.8	1171.7	1469.6	845.2	763	660.9	572.8	445.9	418.1	420.8	256.9	100.6	25.4	237.8	31.9	11.7
cash-flows.row.operating-cash-flow	481.62	389.8	464.6	415.8	665.8	485.2	380.7	396.9	504.9	465	347.4	398.6	228.6	238.1	174.4	194.3	88.4	57.6	47.5	31.3	30.6
cash-flows.row.capital-expenditure	-213.1	-163.5	-236.9	-255.9	-272.8	-227.4	-229.6	-164.2	-129.7	-151	-109.5	-247.9	-73.1	-43	-30.5	-23.6	-26.6	-64.9	-81.2	-17.7	-16.4
cash-flows.row.free-cash-flow	268.53	226.3	227.7	159.9	393	257.8	151.1	232.6	375.2	314	237.9	150.7	155.5	195.1	143.9	170.7	61.8	-7.4	-33.8	13.5	14.1

Kasumiaruande rida

Beijing SL Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga -0.040%. 002038.SZ brutokasum on teatatud 702.76. Ettevõtte tegevuskulud on 491.63, mille muutus võrreldes eelmise aastaga on -30.872%. Kulud amortisatsioonikulud on 113.88, mis on -0.095% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 491.63, mis näitab -30.872% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.198% kasvu võrreldes eelmise aastaga. Tegevustulu on 211.13, mis näitab -0.198% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.778%. Eelmise aasta puhaskasum oli 416.69.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002
income-statement-row.row.total-revenue	962.21	1008.3	1050.2	1214.8	1112.7	2029.7	2167.5	1242.1	1009.8	1156.5	1243	1161.8	1007	622.8	457.8	390	358	237.5	143.9	118.6	93.1	71.1	49.9	32.2
income-statement-row.row.cost-of-revenue	238.91	305.5	157	183.6	163.4	417.4	448.3	364.3	351.3	393.6	372.4	378.6	330.3	153.1	106.7	67	49	81.6	53.1	45.9	32.5	20.6	11.5	4.8
income-statement-row.row.gross-profit	723.3	702.8	893.2	1031.2	949.3	1612.3	1719.2	877.8	658.6	763	870.5	783.2	676.7	469.7	351.1	323	309	155.9	90.8	72.7	60.6	50.4	38.4	27.4
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	166.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	19.27	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	214.73	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-0.99	-1	99.2	82.7	75.6	66.4	-10	1	20.2	11.9	32.4	19.3	5.2	11.4	38	10.2	7	9.6	2.3	1	0.5	0.7	0	0.1
income-statement-row.row.operating-expenses	498.87	491.6	711.2	776.1	779.9	1108.5	1050.1	490.9	196.2	186.2	147.1	175.4	158.8	103.7	93.4	83	75.7	62	41.9	40.1	27.4	18.3	16.6	6.7
income-statement-row.row.cost-and-expenses	737.77	797.1	868.2	959.7	943.3	1525.9	1498.4	855.2	547.4	579.8	519.5	554	489.1	256.8	200.1	150	124.7	143.6	95.1	86	59.9	38.9	16.6	6.7
income-statement-row.row.interest-income	14.77	14.2	15.2	16.8	10.5	26.5	21.9	19.3	18.1	20.3	21.7	12.9	10.8	9	7.3	0	4.8	2.2	3.5	4.6	1.2	0.1	0	0
income-statement-row.row.interest-expense	0	0.1	0.1	0.2	0.4	0.1	20.8	18.3	18	0	0	0	0	0	0	-6.8	0	0	0	0	0.1	0	0	0.1
income-statement-row.row.selling-and-marketing-expenses	214.73	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	53.63	241.5	-4	0.3	-0.1	0	2.6	235.7	65	92	89	65.9	42.5	238.5	61.8	33	2.7	55.2	7.7	4.9	1.5	-0.1	0	-0.1
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-0.99	-1	99.2	82.7	75.6	66.4	-10	1	20.2	11.9	32.4	19.3	5.2	11.4	38	10.2	7	9.6	2.3	1	0.5	0.7	0	0.1
income-statement-row.row.total-operating-expenses	53.63	241.5	-4	0.3	-0.1	0	2.6	235.7	65	92	89	65.9	42.5	238.5	61.8	33	2.7	55.2	7.7	4.9	1.5	-0.1	0	-0.1
income-statement-row.row.interest-expense	0	0.1	0.1	0.2	0.4	0.1	20.8	18.3	18	0	0	0	0	0	0	-6.8	0	0	0	0	0.1	0	0	0.1
income-statement-row.row.depreciation-and-amortization	52.83	145.7	161	134.8	62.3	81.6	55.8	37.5	33.6	32.7	30.7	22.5	20.3	17.6	13.7	12.3	11.9	9.9	7.4	10	9.1	8	-38.4	0.1
income-statement-row.row.ebitda-caps	348.88	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	239.31	211.1	263.3	457.5	412.9	560.9	681.6	621.6	507.2	656.8	780.5	654.6	555.1	593	281.6	262.9	229	139.5	57.4	38.4	35.3	33.2	21.8	20.6
income-statement-row.row.income-before-tax	292.94	452.6	259.4	457.8	412.8	560.9	671.6	622.6	527.4	668.7	812.4	673.7	560.3	604.5	319.6	273	236	149.1	58.2	38.4	35.3	33	21.8	20.6
income-statement-row.row.income-tax-expense	22.25	49.9	31	36.5	51.3	81.4	108.3	93.9	80	91.5	111.4	101.7	80.4	80.1	43.2	29.3	17.6	14.3	7.8	4.6	3.3	1.8	2.6	1.7
income-statement-row.row.net-income	284.9	416.7	234.4	425.9	364.7	486.8	571.4	533.6	452.1	575	695.1	577.4	481	523.3	272.7	244.1	217.9	134.8	50.3	33.8	32	31.2	19.3	18.9